Long-term follow-up for multiple sclerosis patients initially treated with interferon-beta and glatiramer acetate

In previous studies the estimation of the incidence of intellectual changes in multiple sclerosis has varied from as low as 2 per cent. (Cottrell and Wilson, 1926) to as high as 72 per cent. (Ombredane, 1929). In order to establish the incidence accurately, the most satisfactory method would clearly be a long-term follow-up (covering lifetime) of a sample of multiple sclerosis patients. Any cross-sectional study would include patients in varying degrees of advancement of the disease, and patients found to be free of intellectual deficits at the time of investigation would not necessarily remain so. Also, the indirect psychometric assessment of intellectual loss is notoriously difficult, and the direct method of follow-up would give much more accurate results. The only direct study up to date has been that of Canter (1951), who found a highly significant (i.e. 13·48 points) loss on re-testing multiple sclerosis patients on the Army General Classification Test after a four-year period. Even after such a short period as six months he found slight losses on most Wechsler-Bellevue subtests, in contrast to an average gain of six full IQ points of the control group.

Download Full-text

FP39-WE-01 Long-term follow-up 20 years after the pivotal interferon beta-1b multiple sclerosis trial

Journal of the Neurological Sciences ◽

10.1016/s0022-510x(09)70472-1 ◽

2009 ◽

Vol 285 ◽

pp. S118-S119

Author(s):

D.S. Goodin ◽

G. Ebers ◽

G. Cutter ◽

A. Traboulsee ◽

D. Langdon ◽

...

Keyword(s):

Multiple Sclerosis ◽

Interferon Beta ◽

Long Term Follow Up

Download Full-text

Long-term emotional state of multiple sclerosis patients treated with interferon beta

Multiple Sclerosis Journal ◽

10.1177/1352458506070748 ◽

2006 ◽

Vol 12 (6) ◽

pp. 802-807 ◽

Cited By ~ 22

Author(s):

J Porcel ◽

J Río ◽

A Sánchez-Betancourt ◽

M J Arévalo ◽

M Tintoré ◽

...

Keyword(s):

Multiple Sclerosis ◽

Depressive Symptoms ◽

Psychological Assessment ◽

Interferon Beta ◽

Rating Scale ◽

Emotional State ◽

Emotional Assessment ◽

Multiple Sclerosis Patients

Objective: To assess the long-term emotional state of multiple sclerosis (MS) patients treated with interferon beta (IFNβ) for at least four years. Methods: Patients who had started IFNβ therapy prior to 2000 with a baseline psychological assessment were identified and scheduled for long-term emotional assessment with the following questionnaires-the Hamilton Depression Rating Scale, the Beck Depression Inventory and the State-Trait Anxiety Inventory. Results: A total of 262 patients started IFNβ therapy in our MS clinic within the period 1995-1999. Baseline emotional assessment was available from 246 MS patients. Long-term assessment was conducted on 234 patients. After a mean follow-up of 65 months (43-98), 52 patients (22.3%) had withdrawn from IFNβ therapy. The comparisons, obtained from baseline and follow-up scores, showed an improvement in the depressive and anxiety symptoms of patients who adhered to IFNβ treatment. Logistic regression analysis indicated that an increase in physical disability and the presence of depressive symptoms at baseline were best predictors for long-term depressive symptoms. Conclusions: The present results support the absence of emotional worsening in MS patients treated with IFNβ for a long period of time. Increased disability and the presence of baseline depressive symptoms predicted the presence of depressive symptoms at follow-up.

Download Full-text

Real-World Lab Data in Natalizumab Treated Multiple Sclerosis Patients Up to 6 Years Long-Term Follow Up

Frontiers in Neurology ◽

10.3389/fneur.2018.01071 ◽

2018 ◽

Vol 9 ◽

Cited By ~ 11

Author(s):

Maxi Kaufmann ◽

Rocco Haase ◽

Undine Proschmann ◽

Tjalf Ziemssen ◽

Katja Akgün

Keyword(s):

Multiple Sclerosis ◽

Real World ◽

Long Term Follow Up ◽

Multiple Sclerosis Patients

Download Full-text

Long-term follow-up of patients treated with glatiramer acetate: a multicentre, multinational extension of the European/Canadian double-blind, placebo-controlled, MRI-monitored trial

Multiple Sclerosis Journal ◽

10.1177/1352458506070704 ◽

2007 ◽

Vol 13 (4) ◽

pp. 502-508 ◽

Cited By ~ 39

Author(s):

M. Rovaris ◽

G. Comi ◽

MA Rocca ◽

P. Valsasina ◽

D. Ladkani ◽

...

Keyword(s):

Multiple Sclerosis ◽

Glatiramer Acetate ◽

Brain Mri ◽

Treatment Phase ◽

Double Blind ◽

Brain Volumes ◽

Disease Evolution ◽

Long Term Follow Up

Glatiramer acetate (GA) is effective in reducing clinical and magnetic resonance imaging (MRI) activity in relapsing-remitting multiple sclerosis (RRMS). Serial long-term MRI data are lacking for large cohorts of GA-treated patients. The European/Canadian GA study consisted of two consecutive phases, each lasting nine months. The first treatment phase was randomized, double-blind and placebo-controlled. The second was an open-label, active treatment phase with daily administration of 20 mg GA subcutaneously for all patients. For the long-term follow-up (LTFU), dual echo, pre- and postgadolinium T1-weighted brain MRI scans were obtained with the same acquisition scheme as for the original trial and a neurological assessment was performed. Lesion volumes, normalized brain volumes and percentage brain volume changes (PBVC) were measured. One hundred and forty-two (63.4%) of the 224 patients who completed the two phases of the European/Canadian study underwent the LTFU after a mean period of 5.8 years (range: 5.3-6.4); 73 were treated with GA from study initiation. MRI measures at LTFU did not significantly differ between patients originally assigned to placebo and those who were always treated with GA, but the proportion of patients who did not require walking aids at LTFU was lower in the latter group (P=0.034). PBVC between baseline and LTFU was significantly correlated with lesion load at study entry. An earlier initiation of GA treatment in patients with active RRMS might, at least partially, have a favourable impact on long-term disease evolution. Multiple Sclerosis 2007; 13: 502-508. http://msj.sagepub.com

Download Full-text

Thyroid autoimmunity and dysfunction in multiple sclerosis patients during long-term treatment with interferon beta or glatiramer acetate: an Italian multicenter study

Multiple Sclerosis Journal ◽

10.1177/1352458514521311 ◽

2014 ◽

Vol 20 (9) ◽

pp. 1265-1268 ◽

Cited By ~ 7

Author(s):

Giovanni Frisullo ◽

Massimiliano Calabrese ◽

Carla Tortorella ◽

Damiano Paolicelli ◽

Paolo Ragonese ◽

...

Keyword(s):

Multiple Sclerosis ◽

Glatiramer Acetate ◽

Interferon Beta ◽

Thyroid Autoimmunity ◽

Term Treatment ◽

First Year ◽

Close Monitoring ◽

Long Term Treatment ◽

Multiple Sclerosis Patients

Few long-term follow-up data are available on thyroid dysfunction (TD) in multiple sclerosis (MS) patients treated with glatiramer acetate (GA) or with interferon-beta (IFNb). In a cohort of 787 relapsing–remitting MS (RRMS) patients whom were followed up for 8 years, we observed an increased prevalence of TD and thyroid autoimmunity (TA) within the first year of IFNb treatment, regardless of the dose or frequency of administration, while no change was observed with GA treatment. The increased prevalence of TD and TA within the first year of IFNb treatment suggested the need for close monitoring of thyroid function and autoimmunity, though only during the first year of IFNb treatment.

Download Full-text